Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 7/20 | 0.47 |
| ▸ | SRC | P12931 | 4/20 | 0.46 |
| ▸ | TEK | Q02763 | 3/20 | 0.46 |
| ▸ | LCK | P06239 | 3/20 | 0.46 |
| ▸ | HCK | P08631 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | EIF2AK3 | Q9NZJ5 | 3/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | ABL2 | P42684 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | KIF5B | P33176 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.43 |
| ▸ | NEK7 | Q8TDX7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6867037 | 0.89 | SRC (0.53) | RIPK2SRCTEKLCKHCK | |
| SCHEMBL6865175 | 0.87 | KDR (0.52) | RIPK2SRCTEKLCKHCK | |
| SCHEMBL6461270 | 0.85 | RET (0.53) | RIPK2SRCTEKLCKHCK | |
| SCHEMBL6462768 | 0.83 | RET (0.54) | RIPK2SRCTEKLCKHCK | |
| SCHEMBL6460272 | 0.82 | SRC (0.61) | RIPK2SRCTEKLCKHCK | |
| Carbamic Acid SCHEMBL7852916 | 0.81 | SRC (0.60) | RIPK2SRCTEKLCKHCK | |
| SCHEMBL6460851 | 0.79 | RIPK2 (0.60) | RIPK2SRCTEKLCKHCK | |
| SCHEMBL6467947 | 0.78 | RIPK2 (0.53) | RIPK2SRCTEKLCKHCK | |
| SCHEMBL6461293 | 0.77 | SRC (0.54) | RIPK2SRCTEKLCKHCK | |
| SCHEMBL6861029 | 0.77 | LCK (0.59) | RIPK2SRCTEKLCKHCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| WO-2004100868-A2 | METHOD OF TREATING TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2004-11-25 | — | — | WO | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | RIPK2 2575/4885SRC 46/4885TEK 1465/4885 |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | RIPK2 313/4885SRC 206/4885TEK 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.